Physician profile
Allyson E Armas
NPI 1730951799
$948.21
in general payments reported to CMS, 2019-2025
17 companies · $724 in 2025
The $724 reported for 2025 was more than what 93% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $224 · 2025: $724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $948.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $228.80 | 2024-2025 | Myfembree, Gemtesa |
| Exeltis, USA INC. | $144.11 | 2024-2025 | Slynd |
| Pfizer INC. | $141.67 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $66.49 | 2025 | |
| Millicent US INC | $60.46 | 2024-2025 | Intrarosa, Femlyv |
| Shield Therapeutics INC | $49.14 | 2025 | |
| Sage Therapeutics, LLC | $46.49 | 2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $37.83 | 2025 | |
| Astellas Pharma US INC | $28.77 | 2024-2025 | Veozah |
| Octapharma USA, INC. | $21.61 | 2025 | Fibryga |
| Hologic Sales and Service, LLC | $20.12 | 2024 | Fluent Fluid Management System, Myosure Tissue Removal Device, Novasure |
| Smith+Nephew, INC. | $19.74 | 2024 | Stravix |
| Gynesonics, INC. | $19.10 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Vertex Pharmaceuticals Incorporated | $18.68 | 2025 | |
| Ethicon US, LLC | $17.09 | 2025 | Stratafix |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $14.09 | 2024 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $14.02 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allyson Armas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.